West Pharmaceutical Services, Inc. with ticker code (WST) now have 9 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $470.00 and $265.00 suggesting an average Analsyt target price of $353.18. Given that the stocks previous close was at $311.00 and the analysts are correct then we can expect a percentage increase in value of 13.6%. The day 50 moving average is $301.65 and the 200 moving average now moves to $343.49. The total market capitalization for the company now stands at 21.77B. The current share price for the company is: $300.16 USD
The potential market cap would be $24,727,240,335 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 42.76, revenue per share of $39.01 and a 10.66% return on assets.
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates through two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment solutions, and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
